Current perspectives on the use of ancillary materials for the manufacture of cellular therapies-Reference-Cited by-同舟云学术

Current perspectives on the use of ancillary materials for the manufacture of cellular therapies

Published:2016-01 Issue:1 Volume:18 Page:1-12
ISSN:1465-3249
Container-title:Cytotherapy
language:en
Short-container-title:Cytotherapy

Author:

Solomon Jennifer,Csontos Lynn,Clarke Dominic,Bonyhadi Mark,Zylberberg Claudia,McNiece Ian,Kurtzberg Joanne,Bell Rosemarie,Deans Robert

Publisher

Elsevier BV

Subject

Cancer Research,Transplantation,Cell Biology,Genetics(clinical),Oncology,Immunology,Immunology and Allergy

Reference19 articles.

1. 2014 Regenerative Medicine Annual Industry Report;Alliance for Regenerative Medicine,2014

2. Therapies of the state;Schachter;Nature,2014

3. USP <1043> Ancillary Materials for Cell, Gene and Tissue Engineered Products;USP 37,2014

4. Harmonised Tripartite Guideline Pharmaceutical Quality System Q10;International Conference on Harmonization (ICH),2008

5. Draft guideline on the risk-based approach according to Annex I, part IV of Directive 2001/83/EC applied to Advanced Therapy Medicinal Products;European Medicines Agency,2012

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive analysis of secretome and transcriptome stability in WJ-Mesenchymal Stromal Cells across GMP Manufacturing;Cytotherapy;2024-08

2. Umbilical cord mesenchymal stromal cells in serum-free defined medium display an improved safety profile;Stem Cell Research & Therapy;2023-12-12

3. Quality management overview for the production of a tissue-engineered human skin substitute in Malaysia;Stem Cell Research & Therapy;2023-10-20

4. Country-specific regulation and international standardization of cell-based therapeutic products derived from pluripotent stem cells;Stem Cell Reports;2023-08

5. Culturing human pluripotent stem cells for regenerative medicine;Expert Opinion on Biological Therapy;2023-06-03